Labcorp has announced nationwide availability for the Agilent PD-L1 IHC 22C3 pharmDx, a critical companion diagnostic for identifying ovarian cancer patients eligible for Merck’s KEYTRUDA therapy.
Samsung Biologics reports a stellar start to 2026, recording KRW 1,257 billion in revenue and KRW 581 billion in operating profit, fueled by its new U.S. manufacturing presence and Plant 4 utilization.
Novo Nordisk has announced breakthrough results from its PIONEER TEENS trial, proving that oral semaglutide for type 2 diabetes in children offers superior glycemic control and a well-tolerated safety profile for adolescents.
Merck receives Idvynso FDA approval for its once-daily single-tablet regimen of doravirine and islatravir. This breakthrough treatment offers a new option for adults living with HIV-1 who are virologically suppressed.
Sanofi has achieved a historic breakthrough with the expanded Tzield FDA approval for young children. Previously restricted to those aged eight and older, the therapy is now available for children as young as one year old, offering a vital window to delay the onset of clinical Type 1 Diabetes.
Indian health officials have intercepted a shipment of suspected counterfeit weight-loss medication. The discovery of fake Mounjaro pens underscores a growing global trend of illicit medical supplies entering the market through online platforms like Alibaba.
Roche announces positive top-line Enspryng Phase III results from the METEOROID study, demonstrating a significant delay in relapses for patients with MOGAD.
Pfizer and Merck announce that the FDA has accepted a supplemental Biologics License Application (sBLA) for PADCEV in combination with KEYTRUDA for Priority Review in patients with muscle-invasive bladder cancer (MIBC).
AstraZeneca has announced that the Phase III MIRANDA trial for tozorakimab successfully met its primary endpoint, marking the third positive pivotal study for the IL-33-targeting biologic in patients with COPD.
Abbott (NYSE: ABT) has released its first-quarter 2026 financial results, showcasing strong organic growth and the strategic integration of Exact Sciences into its world-leading diagnostics portfolio.
